Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Ophthalmology

Monitoring Your Progress and Acting on Red Flags

At a Glance

Autoimmune uveitis can damage vision even when the eye feels quiet. Keep scheduled eye exams and pressure checks, and seek same-day emergency care for sudden vision loss, a curtain or shower of floaters and flashes, severe pain, or worsening vision after an eye injection.

Living with noninfectious uveitis requires a shift in how you think about your eye health. Because inflammation can be “quiet” while still causing structural changes, regular surveillance is your most powerful tool for preserving long-term vision. Managing this condition is a partnership where your role is to monitor for urgent “red flags” at home while your specialist monitors for silent complications in the clinic [1][2].

When to Seek Urgent Care: The Red Flags

While some complications of uveitis develop slowly and silently, sudden vision loss can occur and requires same-day emergency assessment. Do not “wait and see” if you experience the following:

  • Sudden Vision Loss: Any rapid or marked drop in your ability to see, whether painless or painful [3][4].
  • The “Curtain” or “Shower”: A new shadow or curtain over your vision, or a sudden shower of “floaters” and flashes of light, which can signal a retinal detachment [5][6].
  • Severe Pain or Redness: Intense pain or deep redness that makes it difficult to keep your eye open, especially if accompanied by extreme light sensitivity (photophobia) [7].
  • Post-Injection Warning Signs: If you have recently received an eye injection (such as a steroid implant), seek immediate care for worsening pain, a significant decrease in vision, or a visible “layer” of white cells (hypopyon) in the front of the eye, which could indicate a severe reaction or infection [8][9].

Note: For non-emergency changes—like gradually worsening blur, increasing floaters, medication side effects, or fever—call your uveitis team’s triage line rather than waiting for your next scheduled visit.

Common Complications to Watch For

Vision changes in uveitis are often the result of specific complications that arise from the inflammation itself or from the treatments used to control it [10].

  1. Uveitic Macular Edema (UME): This is a leading cause of vision loss in patients with uveitis [11]. It occurs when blood vessels leak fluid into the macula (the center of the retina responsible for sharp vision) [12]. Because it often starts as a subtle blurring, it is monitored closely using OCT scans [11][13].
  2. High Eye Pressure (Ocular Hypertension) & Glaucoma: This is a “silent” complication because you cannot feel your eye pressure rising [14]. It can be caused by the inflammation itself or as a side effect of steroid treatments [15]. Because long-term high pressure can cause irreversible optic nerve damage (glaucoma), your Intraocular Pressure (IOP) must be checked regularly [16][17].
  3. Cataracts: A clouding of the eye’s natural lens is very common over time, especially with prolonged steroid use [10]. While cataracts are treatable with surgery, your specialist will carefully time the procedure to ensure your inflammation is adequately controlled first [18][17].

Other potential complications include retinal vasculitis, chorioretinal scarring, and epiretinal membranes.

The Long-Term Surveillance Schedule

Even when your eyes feel perfect and your disease is considered “quiescent” (clinically quiet), monitoring must continue. Relapses can occur even while you are on effective medication [1][19].

There is no “one-size-fits-all” schedule. Your visit frequency will vary substantially depending on your subtype, active treatment changes, and history of complications.

  • Active Phase: You may see your doctor very frequently (e.g., weekly) while adjusting medications or tapering steroids [20].
  • Stable Phase: Once remission is achieved, intervals may be extended gradually by your specialist [1].
  • Clinical Assessments: Even if you have no active cells visible under the microscope, your doctor may use tools like OCT or fluorescein angiography when clinically indicated to assess for structural damage, edema, or active vasculitis [21][13].

By staying vigilant and adhering to your individualized monitoring schedule, you and your care team can catch complications early and adjust your treatment to keep your vision stable for years to come [2][22].

Common questions in this guide

Which symptoms of autoimmune uveitis require same-day emergency care?
Seek same-day emergency eye assessment for sudden or marked vision loss, a new curtain or shadow, or a sudden shower of floaters and flashes. Severe eye pain or deep redness with strong light sensitivity, or worsening pain or vision after an eye injection, also needs urgent care; do not wait to see if it improves.
What complications can develop even when noninfectious uveitis feels quiet?
Uveitis can cause swelling in the macula, high eye pressure or glaucoma, cataracts, retinal blood-vessel inflammation, scarring, and epiretinal membranes. Some cause little or no early sensation, so regular examinations and imaging help find them before vision is permanently affected.
Why do I need eye-pressure checks and retinal scans if my vision feels normal?
High eye pressure often has no symptoms and can damage the optic nerve, especially when it is related to uveitis or steroid treatment. Retinal scans such as OCT can reveal fluid or swelling in the macula that may first appear as subtle blur.
How often should I have follow-up visits for autoimmune uveitis?
The schedule is individualized based on whether inflammation is active, whether medicines are changing, and your history of complications. Visits may be as frequent as weekly during medication adjustments or steroid tapering, then spaced farther apart gradually when the disease is stable; monitoring continues even when you feel well.
Can steroid treatment affect my eye pressure or lens?
Yes. Prolonged steroid treatment can raise eye pressure and contribute to glaucoma or cataracts, so your specialist may monitor pressure more closely if you are a steroid responder. Cataract surgery is usually timed after inflammation is adequately controlled.
What should I do about gradual blur or more floaters between visits?
Call your uveitis team’s triage line about gradual blur, increasing floaters, medication side effects, or fever rather than waiting for the next appointment. Seek same-day emergency care instead for sudden vision loss, a curtain or shadow, flashes with a sudden shower of floaters, severe pain, or serious symptoms after an injection.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is my target eye pressure, and how does it compare to my reading today?
  2. 2.Is there any sign of fluid or swelling in my macula (macular edema) on today's OCT scan?
  3. 3.If I experience a sudden increase in floaters or a 'curtain' in my vision after hours, which emergency facility should I go to that has a retinal specialist on call?
  4. 4.Am I a 'steroid responder,' and if so, how does that change my monitoring schedule for glaucoma?
  5. 5.At what point of stable vision will we consider extending the time between my follow-up appointments?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (22)
  1. 1

    Pediatric uveitis: A comprehensive review.

    Maleki A, Anesi SD, Look-Why S, et al.

    Survey of ophthalmology 2022; (67(2)):510-529 doi:10.1016/j.survophthal.2021.06.006.

    PMID: 34181974
  2. 2

    Noninfectious uveitis: strategies to optimize treatment compliance and adherence.

    Dolz-Marco R, Gallego-Pinazo R, Díaz-Llopis M, et al.

    Clinical ophthalmology (Auckland, N.Z.) 2015; (9()):1477-81 doi:10.2147/OPTH.S36650.

    PMID: 26316689
  3. 3

    Syphilitic Outer Retinopathy: A Case Report and Review of the Literature.

    Amaral C, Joy L, Jimenez H, et al.

    Journal of vitreoretinal diseases 2022; (6(1)):63-70 doi:10.1177/24741264211018300.

    PMID: 37007722
  4. 4

    Lessons of the month 2: A case of Behçet's disease: 70% have ophthalmic involvement.

    Auluck I, Karimi A, Taylor S

    Clinical medicine (London, England) 2019; (19(6)):519-522 doi:10.7861/clinmed.2019.0149.

    PMID: 31732597
  5. 5

    Preoperative Inflammatory Control and Surgical Outcome of Vitrectomy in Intermediate Uveitis.

    Shin YU, Shin JY, Ma DJ, et al.

    Journal of ophthalmology 2017; (2017()):5946240 doi:10.1155/2017/5946240.

    PMID: 28465834
  6. 6

    Systemic and ocular complications related to intravitreal administration of anti-VEGF agents.

    Koksaldi S, Kayabasi M, Karti O, Saatci AO

    Medical hypothesis, discovery & innovation ophthalmology journal 2026; (15(1)):40-68 doi:10.51329/mehdiophthal1539.

    PMID: 42083562
  7. 7

    Endophthalmitis caused by Enterococcus faecalis: cytological and bacteriological diagnosis using vitreous fluid.

    Ramtohul P, Frankel D, Gouriet F, et al.

    Journal of ophthalmic inflammation and infection 2025; (15(1)):22 doi:10.1186/s12348-025-00482-w.

    PMID: 40057660
  8. 8

    Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review.

    Anderson WJ, da Cruz NFS, Lima LH, et al.

    International journal of retina and vitreous 2021; (7(1)):37 doi:10.1186/s40942-021-00307-7.

    PMID: 33962696
  9. 9

    Severe Intraocular Inflammation Following Intravitreal Faricimab.

    Thangamathesvaran L, Kong J, Bressler SB, et al.

    JAMA ophthalmology 2024; (142(4)):365-370 doi:10.1001/jamaophthalmol.2024.0530.

    PMID: 38421861
  10. 10

    Risk of Ocular Complications in Patients with Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis.

    Dick AD, Tundia N, Sorg R, et al.

    Ophthalmology 2016; (123(3)):655-62.

    PMID: 26712559
  11. 11

    Frequency and Treatment Regimens of Macular Edema in 1946 Consecutive Patients with Noninfectious Uveitis at a Tertiary Ophthalmic Center in Shaanxi, China.

    Xue YQ, Xiao JA, Chen Y

    Ophthalmology and therapy 2023; (12(5)):2609-2619 doi:10.1007/s40123-023-00763-4.

    PMID: 37440091
  12. 12

    Baseline OCT biomarkers associated with visual prognosis in cystoid macular edema secondary to noninfectious uveitis.

    Bodur MF, Koçak N, Eser-Ozturk H, Sullu Y

    Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 2026; doi:10.1007/s00417-026-07292-3.

    PMID: 42183910
  13. 13

    LONG-TERM OUTCOMES OF RITUXIMAB THERAPY IN PATIENTS WITH NONINFECTIOUS POSTERIOR UVEITIS REFRACTORY TO CONVENTIONAL IMMUNOSUPPRESSIVE THERAPY.

    Lasave AF, You C, Ma L, et al.

    Retina (Philadelphia, Pa.) 2018; (38(2)):395-402 doi:10.1097/IAE.0000000000001563.

    PMID: 28225369
  14. 14

    Characteristics of ocular hypertension and uveitic glaucoma among patients with noninfectious uveitis.

    Felfeli T, Rhee J, Eshtiaghi A, et al.

    Canadian journal of ophthalmology. Journal canadien d'ophtalmologie 2024; (59(6)):430-438 doi:10.1016/j.jcjo.2024.02.003.

    PMID: 38431271
  15. 15

    Risk of Glaucoma in Patients With Idiopathic Noninfectious Uveitis: A Multi-Institutional Real-World Retrospective Cohort Study.

    Liu DY, Kuo HT, Hsu AY, et al.

    American journal of ophthalmology 2026; (285()):63-72 doi:10.1016/j.ajo.2026.01.020.

    PMID: 41592690
  16. 16

    Risk of Ocular Hypertension in Adults with Noninfectious Uveitis.

    Daniel E, Pistilli M, Kothari S, et al.

    Ophthalmology 2017; (124(8)):1196-1208 doi:10.1016/j.ophtha.2017.03.041.

    PMID: 28433444
  17. 17

    Intravitreal Dexamethasone Implant in the Treatment of Non-infectious Uveitis

    Hasanreisoğlu M, Özdemir HB, Özkan K, et al.

    Turkish journal of ophthalmology 2019; (49(5)):250-257 doi:10.4274/tjo.galenos.2019.81594.

    PMID: 31650791
  18. 18

    The 0.2-μg/day Fluocinolone Acetonide Intravitreal Implant in Chronic Noninfectious Posterior Uveitis: A 3-year Randomized Trial in India.

    Biswas J, Tyagi M, Agarwal M,

    Ophthalmology science 2024; (4(1)):100403 doi:10.1016/j.xops.2023.100403.

    PMID: 38027419
  19. 19

    Recurrence Rates of Inflammation after Switching from the Originator Infliximab to Biosimilar Infliximab-abda for Noninfectious Uveitis.

    Deaner JD, Srivastava SK, Hajj-Ali RA, et al.

    American journal of ophthalmology 2021; (225()):172-177 doi:10.1016/j.ajo.2020.08.005.

    PMID: 32795432
  20. 20

    Dexamethasone Inserts in Noninfectious Uveitis: A Single-Center Experience.

    Pohlmann D, Vom Brocke GA, Winterhalter S, et al.

    Ophthalmology 2018; (125(7)):1088-1099 doi:10.1016/j.ophtha.2017.12.038.

    PMID: 29459041
  21. 21

    Blood-Ocular Barrier Dysfunction in Uveitis: A Bidirectional Model Linking Pathogenesis, Clinical Monitoring, and Therapeutic Opportunities.

    Chen Y, Yang M, Zou Y, et al.

    Medical sciences (Basel, Switzerland) 2026; (14(2)) doi:10.3390/medsci14020290.

    PMID: 42346829
  22. 22

    Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis: Fundamentals Of Care for UveitiS (FOCUS) Initiative.

    Dick AD, Rosenbaum JT, Al-Dhibi HA, et al.

    Ophthalmology 2018; (125(5)):757-773 doi:10.1016/j.ophtha.2017.11.017.

    PMID: 29310963

This page is for informational purposes only and does not constitute medical advice. If you have sudden vision loss, a curtain or shower of floaters and flashes, severe eye pain, or worsening vision after an eye injection, seek same-day emergency assessment.

Get notified when new evidence is published on autoimmune uveitis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.